Compass Therapeutics (CMPX) Other Accumulated Expenses (2023 - 2025)
Historic Other Accumulated Expenses for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $141000.0.
- Compass Therapeutics' Other Accumulated Expenses fell 1556.89% to $141000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $141000.0, marking a year-over-year decrease of 1556.89%. This contributed to the annual value of $621000.0 for FY2024, which is 15875.0% up from last year.
- Per Compass Therapeutics' latest filing, its Other Accumulated Expenses stood at $141000.0 for Q3 2025, which was down 1556.89% from $384000.0 recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Other Accumulated Expenses ranged from a high of $621000.0 in Q4 2024 and a low of $137000.0 during Q1 2023
- For the 3-year period, Compass Therapeutics' Other Accumulated Expenses averaged around $290818.2, with its median value being $274000.0 (2025).
- Examining YoY changes over the last 5 years, Compass Therapeutics' Other Accumulated Expenses showed a top increase of 15875.0% in 2024 and a maximum decrease of 5728.9% in 2024.
- Compass Therapeutics' Other Accumulated Expenses (Quarter) stood at $240000.0 in 2023, then soared by 158.75% to $621000.0 in 2024, then tumbled by 77.29% to $141000.0 in 2025.
- Its Other Accumulated Expenses was $141000.0 in Q3 2025, compared to $384000.0 in Q2 2025 and $274000.0 in Q1 2025.